Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd is actively engaging investors through a roadshow to update them on its promising antiviral drug developments, including the Phase 2a/b trial of ISLA-101 for dengue fever. The company is also exploring potential opportunities with its second asset, Galidesivir, signaling a dynamic phase with significant milestones ahead.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.